Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 13, 2021
Reporting Period: Quarter ended March 31, 2021
Context: The filing provides an update on developments related to the Company's vaccine against COVID-19, specifically detailing the number of doses delivered during the first quarter of 2021.
Key Financial Metrics and Operational Data
This filing focuses on operational delivery metrics rather than comprehensive financial statements. Specific revenue, profit, cash flow, margin, debt, or liquidity figures are not provided in this text.
- Vaccine Doses Delivered (Q1 2021): 102 million total doses.
- Deliveries to U.S. Government: 88 million doses.
- Deliveries to Other Customers: 14 million doses.
Material Changes
The filing reports the execution of vaccine delivery obligations for the quarter ended March 31, 2021. No comparative data for the prior period is included in this specific 8-K text to quantify material changes in delivery volume.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) incorporated by reference to provide the delivery update.
Legal Disclaimer: The information in this Current Report and the attached press release is intended to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for additional context on pricing or revenue recognition associated with the 102 million doses delivered.
- Review the Company's most recent Form 10-Q or 10-K for detailed financial metrics (revenue, cash flow, debt) as this 8-K does not contain them.
- Confirm the breakdown of "other customers" to understand the geographic or institutional distribution of the 14 million non-U.S. Government doses.
